GlassScriptPhysician profile
Hemen Padhiar
NPI 1740265099
$2,144.60
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.98 · 2021: $48.23 · 2022: $326 · 2023: $599 · 2024: $685 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.78 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.98 | 2020-2025 | |
| Glaxosmithkline, LLC. | $211.19 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $196.98 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $157.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $155.89 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $150.29 | 2022-2025 | Mounjaro, Jardiance, Kisunla |
| Janssen Pharmaceuticals, INC | $134.17 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $133.90 | 2022-2023 | |
| Eisai INC. | $120.07 | 2024-2025 | |
| Pfizer INC. | $110.43 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $78.28 | 2022-2024 | Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $52.50 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $43.81 | 2022 | |
| Abbott Laboratories | $39.93 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $29.11 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $28.31 | 2025 | Inspire |
| Dexcom, INC. | $27.58 | 2023 | Dexcom G6 Transmitter |
| Biogen, INC. | $25.45 | 2025 | Leqembi |
| Xeris Pharmaceuticals, INC. | $23.69 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $22.42 | 2024-2025 | Voquezna |
| Medtronic, INC. | $19.87 | 2025 | Interstim |
| Esperion Therapeutics, INC. | $18.06 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.80 | 2024 | Caplyta |
| Amgen INC. | $15.59 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $15.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemen Padhiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.